{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T07:15:14Z","timestamp":1792134914344,"version":"4.4.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T00:00:00Z","timestamp":1748822400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T00:00:00Z","timestamp":1748822400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum W\u00fcrzburg"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>This study evaluates safety and efficacy of peptide receptor radionuclide therapy (PRRT) as a stand-alone treatment for recurrent meningiomas and investigates the prognostic value of laboratory markers and quantitative PET parameters.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      The single-center study includes 32 patients with recurrent meningioma, who underwent PRRT with [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-DOTATOC\/-TATE. Pre-treatment assessments comprised [\n                      <jats:sup>68<\/jats:sup>\n                      \u00a0Ga]Ga-DOTATOC PET imaging, routine hematology and serum chemistry analysis. Outcomes including progression-free survival (PFS), overall survival (OS), and treatment related toxicity, were retrospectively evaluated using Kaplan\u2013Meier survival analysis and Cox regression models.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      PRRT showed only mild hematological and renal toxicity, with most adverse events being low-grade (87%). OS was significantly shorter in patients with WHO grade III meningiomas (10\u00a0months) compared to grade I (not reached, HR 4.77,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01) and grade II (47\u00a0months, HR 4.05,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.01). Similarly, PFS was shorter in patients with WHO grade III meningiomas (4.5\u00a0months) compared to grade I (17\u00a0months, HR 6.47,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) and grade II (17\u00a0months, HR 2.71,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.02). In multivariable analysis, only higher WHO grade was an independent predictor of disease progression, while baseline PET and laboratory parameters showed no consistent association. Furthermore, increase of SSTR-positive tumor volume in follow-up PET was associated with shorter PFS (HR 1.02,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.02).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>PRRT is a safe treatment option and appears to have a favourable effect in patients with recurrent meningiomas. WHO tumor grade is the strongest predictor of PFS and OS, while baseline PET parameters appear to have no prognostic value.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00259-025-07336-6","type":"journal-article","created":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T03:05:32Z","timestamp":1748833532000},"page":"116-127","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["SSTR-directed peptide receptor radionuclide therapy for recurrent meningiomas: analysis of safety, efficacy and prognostic factors"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-4681-5457","authenticated-orcid":false,"given":"Natalie","family":"Hasenauer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heribert","family":"H\u00e4nscheid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian E.","family":"Serfling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Michalski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marieke","family":"Heinrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00fclent","family":"Polat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas K.","family":"Buck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf A.","family":"Werner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp E.","family":"Hartrampf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,2]]},"reference":[{"issue":"Suppl 5","key":"7336_CR1","doi-asserted-by":"publisher","first-page":"v1","DOI":"10.1093\/neuonc\/noac202","volume":"24","author":"QT Ostrom","year":"2022","unstructured":"Ostrom QT, et al. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2015\u20132019. Neuro Oncol. 2022;24(Suppl 5):v1\u201395.","journal-title":"Neuro Oncol"},{"issue":"8","key":"7336_CR2","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis DN, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021;23(8):1231\u201351.","journal-title":"Neuro Oncol"},{"issue":"11","key":"7336_CR3","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1093\/neuonc\/noab150","volume":"23","author":"R Goldbrunner","year":"2021","unstructured":"Goldbrunner R, et al. EANO guideline on the diagnosis and management of meningiomas. Neuro Oncol. 2021;23(11):1821\u201334.","journal-title":"Neuro Oncol"},{"issue":"3","key":"7336_CR4","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1093\/neuonc\/nov183","volume":"18","author":"J Furtner","year":"2016","unstructured":"Furtner J, et al. Kinetics of tumor size and peritumoral brain edema before, during, and after systemic therapy in recurrent WHO grade II or III meningioma. Neuro Oncol. 2016;18(3):401\u20137.","journal-title":"Neuro Oncol"},{"issue":"2","key":"7336_CR5","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"Strosberg J, et al. Phase 3 Trial of (177)Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med. 2017;376(2):125\u201335.","journal-title":"N Engl J Med"},{"issue":"5","key":"7336_CR6","first-page":"761","volume":"63","author":"G Tamborino","year":"2022","unstructured":"Tamborino G, et al. Modeling Early Radiation DNA Damage Occurring During (177)Lu-DOTATATE Radionuclide Therapy. J Nucl Med. 2022;63(5):761\u20139.","journal-title":"J Nucl Med"},{"issue":"3","key":"7336_CR7","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s00401-015-1459-3","volume":"130","author":"JR Menke","year":"2015","unstructured":"Menke JR, et al. Somatostatin receptor 2a is a more sensitive diagnostic marker of meningioma than epithelial membrane antigen. Acta Neuropathol. 2015;130(3):441\u20133.","journal-title":"Acta Neuropathol"},{"issue":"10","key":"7336_CR8","first-page":"13185","volume":"8","author":"CB Silva","year":"2015","unstructured":"Silva CB, et al. Expression of somatostatin receptors (SSTR1-SSTR5) in meningiomas and its clinicopathological significance. Int J Clin Exp Pathol. 2015;8(10):13185\u201392.","journal-title":"Int J Clin Exp Pathol"},{"issue":"5","key":"7336_CR9","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1002\/(SICI)1097-0215(19980529)76:5<620::AID-IJC2>3.0.CO;2-S","volume":"76","author":"A Dutour","year":"1998","unstructured":"Dutour A, et al. Expression of somatostatin receptor subtypes in human brain tumors. Int J Cancer. 1998;76(5):620\u20137.","journal-title":"Int J Cancer"},{"issue":"9","key":"7336_CR10","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.2967\/jnumed.123.266956","volume":"65","author":"S Severi","year":"2024","unstructured":"Severi S, et al. Peptide Receptor Radionuclide Therapy in Advanced Refractory Meningiomas: Efficacy and Toxicity in a Long Follow-up. J Nucl Med. 2024;65(9):1409\u201315.","journal-title":"J Nucl Med"},{"issue":"8","key":"7336_CR11","doi-asserted-by":"publisher","first-page":"5550","DOI":"10.3390\/curroncol29080438","volume":"29","author":"B Salgues","year":"2022","unstructured":"Salgues B, et al. Somatostatin Receptor Theranostics for Refractory Meningiomas. Curr Oncol. 2022;29(8):5550\u201365.","journal-title":"Curr Oncol"},{"issue":"4","key":"7336_CR12","doi-asserted-by":"publisher","first-page":"507","DOI":"10.2967\/jnumed.120.249607","volume":"62","author":"C Mirian","year":"2021","unstructured":"Mirian C, et al. Somatostatin Receptor-Targeted Radiopeptide Therapy in Treatment-Refractory Meningioma: Individual Patient Data Meta-analysis. J Nucl Med. 2021;62(4):507\u201313.","journal-title":"J Nucl Med"},{"issue":"10","key":"7336_CR13","first-page":"1599","volume":"47","author":"M van Essen","year":"2006","unstructured":"van Essen M, et al. Effects of therapy with [177Lu-DOTA0, Tyr3]octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma. J Nucl Med. 2006;47(10):1599\u2013606.","journal-title":"J Nucl Med"},{"issue":"5","key":"7336_CR14","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1055\/a-1200-0989","volume":"59","author":"M M\u00fcther","year":"2020","unstructured":"M\u00fcther M, et al. Response assessment of somatostatin receptor targeted radioligand therapies for progressive intracranial meningioma. Nuklearmedizin. 2020;59(5):348\u201355.","journal-title":"Nuklearmedizin"},{"issue":"11","key":"7336_CR15","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.2967\/jnumed.115.155853","volume":"56","author":"K Gerster-Gilli\u00e9ron","year":"2015","unstructured":"Gerster-Gilli\u00e9ron K, et al. 90Y-DOTATOC as a Therapeutic Option for Complex Recurrent or Progressive Meningiomas. J Nucl Med. 2015;56(11):1748\u201351.","journal-title":"J Nucl Med"},{"issue":"11","key":"7336_CR16","first-page":"1538","volume":"18","author":"K Seystahl","year":"2016","unstructured":"Seystahl K, et al. Somatostatin receptor-targeted radionuclide therapy for progressive meningioma: benefit linked to 68Ga-DOTATATE\/-TOC uptake. Neuro Oncol. 2016;18(11):1538\u201347.","journal-title":"Neuro Oncol"},{"issue":"2","key":"7336_CR17","doi-asserted-by":"publisher","first-page":"171","DOI":"10.2967\/jnumed.114.147256","volume":"56","author":"N Marincek","year":"2015","unstructured":"Marincek N, et al. Somatostatin receptor-targeted radiopeptide therapy with 90Y-DOTATOC and 177Lu-DOTATOC in progressive meningioma: long-term results of a phase II clinical trial. J Nucl Med. 2015;56(2):171\u20136.","journal-title":"J Nucl Med"},{"issue":"4","key":"7336_CR18","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1158\/1078-0432.CCR-23-2533","volume":"30","author":"SC Kurz","year":"2024","unstructured":"Kurz SC, et al. Evaluation of the SSTR2-targeted Radiopharmaceutical 177Lu-DOTATATE and SSTR2-specific 68Ga-DOTATATE PET as Imaging Biomarker in Patients with Intracranial Meningioma. Clin Cancer Res. 2024;30(4):680\u20136.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"7336_CR19","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nmeth.2019","volume":"9","author":"J Schindelin","year":"2012","unstructured":"Schindelin J, et al. Fiji: an open-source platform for biological-image analysis. Nat Methods. 2012;9(7):676\u201382.","journal-title":"Nat Methods"},{"issue":"10","key":"7336_CR20","doi-asserted-by":"publisher","first-page":"e0140830","DOI":"10.1371\/journal.pone.0140830","volume":"10","author":"S Kanoun","year":"2015","unstructured":"Kanoun S, et al. Influence of Software Tool and Methodological Aspects of Total Metabolic Tumor Volume Calculation on Baseline [18F]FDG PET to Predict Survival in Hodgkin Lymphoma. PLoS One. 2015;10(10):e0140830.","journal-title":"PLoS One"},{"key":"7336_CR21","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) v5.0. U.S. Department of Health and Human Services. Published: November 27, 2017. Available from: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm."},{"issue":"1","key":"7336_CR22","doi-asserted-by":"publisher","first-page":"75","DOI":"10.2967\/jnumed.117.193706","volume":"59","author":"H H\u00e4nscheid","year":"2018","unstructured":"H\u00e4nscheid H, et al. Dose Mapping After Endoradiotherapy with (177)Lu-DOTATATE\/DOTATOC by a Single Measurement After 4 Days. J Nucl Med. 2018;59(1):75\u201381.","journal-title":"J Nucl Med"},{"issue":"6","key":"7336_CR23","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1093\/neuonc\/not330","volume":"16","author":"T Kaley","year":"2014","unstructured":"Kaley T, et al. Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review. Neuro Oncol. 2014;16(6):829\u201340.","journal-title":"Neuro Oncol"},{"issue":"1","key":"7336_CR24","doi-asserted-by":"publisher","first-page":"133","DOI":"10.7150\/thno.88619","volume":"14","author":"RP Baum","year":"2024","unstructured":"Baum RP, et al. Peptide receptor radionuclide therapy (PRRT) in metastatic neuroendocrine tumors of unknown primary (CUP-NETs). Theranostics. 2024;14(1):133\u201342.","journal-title":"Theranostics"},{"issue":"2","key":"7336_CR25","doi-asserted-by":"publisher","first-page":"451","DOI":"10.7150\/thno.92487","volume":"14","author":"RP Baum","year":"2024","unstructured":"Baum RP, et al. Long-term Nephrotoxicity after PRRT: Myth or Reality. Theranostics. 2024;14(2):451\u20139.","journal-title":"Theranostics"},{"issue":"1","key":"7336_CR26","first-page":"vdac123","volume":"4","author":"P Kumthekar","year":"2022","unstructured":"Kumthekar P, et al. A multi-institutional phase II trial of bevacizumab for recurrent and refractory meningioma. Neurooncol Adv. 2022;4(1):vdac123.","journal-title":"Neurooncol Adv"},{"issue":"1","key":"7336_CR27","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1093\/neuonc\/nou148","volume":"17","author":"TJ Kaley","year":"2015","unstructured":"Kaley TJ, et al. Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma. Neuro Oncol. 2015;17(1):116\u201321.","journal-title":"Neuro Oncol"},{"issue":"1","key":"7336_CR28","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s11060-012-0886-4","volume":"109","author":"L Nayak","year":"2012","unstructured":"Nayak L, et al. Atypical and anaplastic meningiomas treated with bevacizumab. J Neurooncol. 2012;109(1):187\u201393.","journal-title":"J Neurooncol"},{"issue":"1","key":"7336_CR29","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s11060-012-0861-0","volume":"109","author":"E Lou","year":"2012","unstructured":"Lou E, et al. Bevacizumab therapy for adults with recurrent\/progressive meningioma: a retrospective series. J Neurooncol. 2012;109(1):63\u201370.","journal-title":"J Neurooncol"},{"issue":"1","key":"7336_CR30","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1007\/s10143-024-02889-w","volume":"47","author":"B Hajikarimloo","year":"2024","unstructured":"Hajikarimloo B, et al. Application of bevacizumab in the management of meningiomas: a systematic review and meta-analysis. Neurosurg Rev. 2024;47(1):692.","journal-title":"Neurosurg Rev"},{"issue":"4","key":"7336_CR31","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1056\/NEJM197201272860407","volume":"286","author":"MM Kaplan","year":"1972","unstructured":"Kaplan MM. Alkaline phosphatase. N Engl J Med. 1972;286(4):200\u20132.","journal-title":"N Engl J Med"},{"issue":"15","key":"7336_CR32","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1016\/j.clinbiochem.2013.06.012","volume":"46","author":"RM Nanau","year":"2013","unstructured":"Nanau RM, Neuman MG. Adverse drug reactions induced by valproic acid. Clin Biochem. 2013;46(15):1323\u201338.","journal-title":"Clin Biochem"},{"key":"7336_CR33","doi-asserted-by":"publisher","first-page":"9800","DOI":"10.1038\/srep09800","volume":"5","author":"J Zhang","year":"2015","unstructured":"Zhang J, et al. Prognostic value of pretreatment serum lactate dehydrogenase level in patients with solid tumors: a systematic review and meta-analysis. Sci Rep. 2015;5:9800.","journal-title":"Sci Rep"},{"key":"7336_CR34","doi-asserted-by":"publisher","first-page":"748586","DOI":"10.3389\/fonc.2021.748586","volume":"11","author":"P Gao","year":"2021","unstructured":"Gao P, et al. A Clinical Prognostic Model Based on Preoperative Hematological and Clinical Parameters Predicts the Progression of Primary WHO Grade II Meningioma. Front Oncol. 2021;11:748586.","journal-title":"Front Oncol"},{"key":"7336_CR35","doi-asserted-by":"publisher","first-page":"889844","DOI":"10.3389\/fonc.2022.889844","volume":"12","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Gu D. Prognostic Impact of Serum CRP Level in Head and Neck Squamous Cell Carcinoma. Front Oncol. 2022;12:889844.","journal-title":"Front Oncol"},{"key":"7336_CR36","doi-asserted-by":"publisher","first-page":"103419","DOI":"10.1016\/j.critrevonc.2021.103419","volume":"164","author":"MW Socha","year":"2021","unstructured":"Socha MW, et al. C-reactive protein as a diagnostic and prognostic factor of endometrial cancer. Crit Rev Oncol Hematol. 2021;164:103419.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"12","key":"7336_CR37","doi-asserted-by":"publisher","first-page":"4262","DOI":"10.1007\/s00259-022-05853-2","volume":"49","author":"PE Hartrampf","year":"2022","unstructured":"Hartrampf PE, et al. Baseline clinical characteristics predict overall survival in patients undergoing radioligand therapy with [(177)Lu]Lu-PSMA I&T during long-term follow-up. Eur J Nucl Med Mol Imaging. 2022;49(12):4262\u201370.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"7336_CR38","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1007\/s12032-013-0705-6","volume":"30","author":"H Eggers","year":"2013","unstructured":"Eggers H, et al. Serum C-reactive protein: a prognostic factor in metastatic urothelial cancer of the bladder. Med Oncol. 2013;30(4):705.","journal-title":"Med Oncol"},{"issue":"10","key":"7336_CR39","doi-asserted-by":"publisher","first-page":"7089","DOI":"10.1007\/s00330-023-09697-8","volume":"33","author":"C Boursier","year":"2023","unstructured":"Boursier C, et al. Semi-automated segmentation methods of SSTR PET for dosimetry prediction in refractory meningioma patients treated by SSTR-targeted peptide receptor radionuclide therapy. Eur Radiol. 2023;33(10):7089\u201398.","journal-title":"Eur Radiol"},{"issue":"3","key":"7336_CR40","doi-asserted-by":"publisher","first-page":"217","DOI":"10.23736\/S1824-4785.24.03571-4","volume":"68","author":"C Boursier","year":"2024","unstructured":"Boursier C, et al. 177Lu-labeled somatostatin receptor targeted radionuclide therapy dosimetry in meningioma: a systematic review. Q J Nucl Med Mol Imaging. 2024;68(3):217\u201325.","journal-title":"Q J Nucl Med Mol Imaging"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07336-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07336-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07336-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T05:05:36Z","timestamp":1764219936000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07336-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,2]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["7336"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07336-6","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,2]]},"assertion":[{"value":"11 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted according to the guidelines of the Declaration of Helsinki. Ethical review and approval were waived for this study by the local Ethics Committee due to the retrospective character of the study (waiver number 2022072501).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional review board"}},{"value":"Informed consent was obtained from all subjects involved in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"A.K.B. and K.M. have received speaker honoraria from Novartis. R.A.W. has received speaker honoraria from Novartis and PentixaPharm and reports advisory board work for Novartis\/AAA and Bayer. All other authors declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}